Cel Sci Corporation (CVM)

[Dr. Johnny Fever]

As I understand it, the company was required to provide results for the overall endpoint for the entire test group (i.e. all patients who received Multikine prior to Standard of Care). The goal for this group was a 10% improvement in Overall Survivability (OS). The trial did NOT meet that goal for the entire test group. This is what the nay-sayers are referring to when they say the trial failed.

However, as was pre-specified in the trial design, the test group was divided into two "subgroups": a group receiving MK plus SOC which included surgery, chemo, and radiation; and a group receiving MK plus SOC which included only surgery and radiation (no chemo).

The chemo subgroup did not see a benefit from MK. The non-chemo subgroup (about 40% of the patients in the test group) saw a 14.1% improvement in OS at 5 years, which handily beat the 10% improvement endpoint.